A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Trial Profile

A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs Reslizumab (Primary)
  • Indications Asthma; Eosinophilia
  • Focus Registrational; Therapeutic Use
  • Acronyms BREATH
  • Sponsors Cephalon; Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 06 Sep 2017 According to a Teva Pharmaceutical Industries media release, data from this and other (NCT01287039) trial will be presented at the 2017 European Respiratory Society (ERS) International Congress in Milan, Italy on September 9-13, 2017.
    • 06 Jul 2017 According to a Teva Pharmaceutical Industries media release, based on the data from two phase III studies (3082 and 3083), the German Federal Joint Committee (G-BA) has confirmed that CINQAERO provides evidence for a minor additional benefit in patients with severe eosinophilic asthma who were treated regularly with corticosteroids in addition to the treatment for acute exacerbations.
    • 24 May 2017 Results of a pooled post-hoc analysis assessing the impact of reslizumab treatment on healthcare resource utilization in patients from two phase III, 52-week trials (BREATH program; n=953) presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top